长春高新(000661) - 2015 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2015 was CNY 240,263.72 million, an increase of 6.20% compared to the previous year[3] - Operating profit reached CNY 61,831.77 million, reflecting a growth of 15.19% year-over-year[3] - Net profit attributable to shareholders was CNY 38,224.52 million, up by 20.14% from the prior year[3] - Basic earnings per share increased to CNY 2.91, representing a growth of 20.25%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 385,533.24 million, a rise of 22.45% from the beginning of the period[3] - Shareholders' equity attributable to the parent company was CNY 177,664.02 million, increasing by 21.67%[3] - The company's net asset per share attributable to shareholders rose to CNY 13.53, an increase of 21.67%[3] Revenue and Profit Drivers - The increase in revenue and profit was primarily driven by the profit growth of the company's pharmaceutical subsidiaries[4] Performance Consistency - There were no discrepancies between the reported performance and previous earnings forecasts[5] Return on Assets - The weighted average return on net assets was 23.78%, slightly up from 23.55% in the previous year[3]